OBJECTIVE: To evaluate the potential efficacy of bupropion sustained release when used in combination with minimal counseling for moist snuff cessation in males. METHODS: A double-blind, placebo-controlled 3-month trial. The active treatment group (n = 35) received bupropion SR at 150 mg/qd day for the first 3 days, then beginning day 4 through day 49 (7 weeks) 150 mg/ b.i.d. The placebo group (n= 35) received 1 tablet qd for 3 days and beginning day 4 through day 49, 1 tablet/b.i.d. RESULTS:Bupropion 300 mg/day (150 b.i.d.) produced significantly higher quit rates for smokeless tobacco cessation at the end of treatment (7 weeks) than placebo (p = 0.04) with an OR of 2.73. CONCLUSION:Bupropion SR appears to be effective for smokeless tobacco cessation.
RCT Entities:
OBJECTIVE: To evaluate the potential efficacy of bupropion sustained release when used in combination with minimal counseling for moist snuff cessation in males. METHODS: A double-blind, placebo-controlled 3-month trial. The active treatment group (n = 35) received bupropion SR at 150 mg/qd day for the first 3 days, then beginning day 4 through day 49 (7 weeks) 150 mg/ b.i.d. The placebo group (n= 35) received 1 tablet qd for 3 days and beginning day 4 through day 49, 1 tablet/b.i.d. RESULTS:Bupropion 300 mg/day (150 b.i.d.) produced significantly higher quit rates for smokeless tobacco cessation at the end of treatment (7 weeks) than placebo (p = 0.04) with an OR of 2.73. CONCLUSION:Bupropion SR appears to be effective for smokeless tobacco cessation.
Authors: Lowell C Dale; Jon O Ebbert; Elbert D Glover; Ivana T Croghan; Darrell R Schroeder; Herbert H Severson; Richard D Hurt Journal: Drug Alcohol Depend Date: 2007-03-13 Impact factor: 4.492